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Background: Activation of protein kinase AKT is required for cardioprotection by ischemic preconditioning, and
transgenic overexpression of AKT protects the heart against ischemia. However, it is unknown whether acute
pharmacological activation of AKT alone, using a therapeutically relevant strategy, induces cardioprotection. In this
study we provide the first evidence to clarify this question.
Methods: We used a recently described specific activator of AKT, the small molecule SC79, to treat rat hearts
submitted to ischemia and reperfusion. Initially, isolated rat hearts were perfused with increasing doses of SC79 to
verify the magnitude of AKT activation. Low and high doses were determined and used to treat hearts submitted
to ischemia (35 minutes) and reperfusion (60 minutes), in a randomized and blinded design. AKT activation was
verified by western immunobloting. Metabolic profile was determined by cardiac ATP content and mitochondrial
enzyme activity, while cytosolic levels of cytochrome C and caspase-3 activity were used as markers of apoptosis.
Ischemic injury was assessed by quantification of infarct size and cardiac release of creatine kinase and lactate
dehydrogenase.
Results: SC79 activated cardiac AKT within 30 minutes in a dose-dependent fashion. ATP content was largely
reduced by ischemia, but was not rescued by SC79. Similarly, mitochondrial enzyme activity was not affected by
SC79. SC79 administered before ischemia or at reperfusion did not prevent cytosolic accumulation of cytochrome C
and overactivation of caspase-3. Finally, SC79 failed to reduce infarct size or release of cardiac injury biomarkers at
reperfusion.
Conclusion: We conclude that selective AKT activation by the synthetic molecule SC79 does not protect the rat heart
against ischemic injury, indicating that acute pharmacological activation of AKT is not sufficient for cardioprotection.
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Reestablishment of coronary blood flow after myocardial
infarction (MI) is the most effective therapy to limit in-
farct size in humans [1]. However, cardiac injury is still
observed even after successful revascularization [2], and
studies showed that infarct size can be reduced by con-
ditioning the heart with brief intermittent ischemic epi-
sodes, either before restoration of blood flow [3] or
immediately at reperfusion [4].
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unless otherwise stated.limiting effects in patients undergoing surgical revasculari-
zation of the myocardium [3-6], which raised a general hy-
pothesis that intracellular mechanisms recruited by these
interventions would be attractive molecular targets for
pharmacological cardioprotection [7]. Based on this prem-
ise, experimental studies identified a network of proteins
associated with cardioprotection by ischemic conditioning,
commonly referred to as RISK (Reperfusion Injury Salvage
Kinases), where AKT (or Protein Kinase B, PKB) plays a
central role [7]. Blocking AKT activation abrogates the
benefits of ischemic preconditioning [8], remote ische-
mic preconditioning [9] or ischemic postconditioning
[10]. Remarkably, these results have been demonstrated
in vivo both in rodents [11] and pigs [9]. In addition,
we have recently demonstrated that remote ischemicl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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patients undergoing cardiac surgery [12].
Studies also showed that rodents with transgenic over-
activation of AKT display reduced infarct size after cor-
onary artery ligation when compared to controls [13-15].
These reports provided a valuable proof-of-concept,
however, genetic activation of AKT in embryonic stages
[15] is not a therapeutic option for humans, and pre-
ventive AKT gene therapy [13,14] is not feasible in the
clinic because it is impossible to predict when a patient
will suffer MI. Therefore, it is unknown whether acute
activation of AKT with a therapeutically relevant strat-
egy protects the heart against ischemia. In order to de-
cide if cardiac AKT should be targeted in patients
suffering MI, it is necessary to answer this question.
To clarify this issue, we used a novel selective activator
of AKT, the small molecule SC79, recently described by
Jo et al. [16]. SC79 binds specifically the PH domain
(pleckstrin homology domain) of AKT, inducing a con-
formational change that favors its activation [16]. Im-
portantly, their data show SC79 is cell-permeable, does
not have side-effects in mice and interacts with AKT in
human-derived cells, indicating that the molecule could
possibly be administered intravenously in patients. Along
with a detailed characterization of the molecule, the au-
thors also reported that pretreatment with SC79 rescued
neuronal cells from ischemic damage. For these reasons,
we hypothesized that SC79 would protect the heart
against ischemia-reperfusion injury.
To test this hypothesis, we treated isolated perfused
rat hearts with low and high doses of SC79, at different
time points (acutely before ischemia, immediately at re-
perfusion or both), and performed a comprehensive ana-
lysis of cardiac damage.
Methods
Animals
Female Sprague–Dawley rats (200-220 g) were used.
Rats were acclimatized to our animal facilities for seven
days before the experiments. Animals were housed four
per cage (22°C) and had free access to standard chow
and water. All experiments were approved by the Nor-
wegian Animal Research Authority before the start of
the project (FOTS#6461).
Isolated heart perfusion
Animals were anesthetized with isoflurane, heparinized
and the heart was quickly excised. The hearts were im-
mediately perfused with the Langendorff retrograde per-
fusion system in constant flow (10 mL/min) with
oxygenated Krebs-Henseleit buffer (37°C), comprised of
118 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 5 mM
glucose, 1.2 mM KH2PO4, 1.2 mM MgSO4 and 1.2 mM
CaCl2 (pH 7.4). This model is extensively used inpreclinical studies on myocardial protection [17] due to
high reproducibility and minimal experimental dropout
rate, thereby avoiding excessive use of experimental
animals.Dose–response experiment with SC79
The small molecule activator of AKT (referred to as
SC79) was purchased from Tocris Biosciences (product
#4635). For dose–response experiments, hearts were
perfused with increasing doses of SC79 for 30 min, in a
randomized fashion. The same concentration of DMSO
(vehicle, 0.01%) was administered to the control group.
The investigators conducting the experiments (J.B.N.M.
and M.W.) were blinded to treatment assignment
(DMSO or SC79). After perfusion, hearts were removed
from the rig and snap-frozen in liquid nitrogen. A sam-
ple from the left ventricle was used to determine AKT
activation by western immunobloting (protocol below).
100nM was adopted as low-activating dose and 300nM
was adopted as high-activating dose (Figure 1A).SC79 treatment of ischemic hearts
Low- and high-activating doses of SC79 were used to
treat hearts submitted to ischemia and reperfusion (IR).
Treatments were performed either before ischemia, at
reperfusion or both. Same concentration of DMSO
(0.01%) was added to the buffer of normoxic perfused
hearts and ischemic control hearts. Experimental groups
are illustrated in Figure 2A and described as: (group “N”)
normoxic hearts, perfused continuously for 125 min;
(IR-Control) ischemic DMSO-treated control group,
hearts perfused for 30 min with normoxic buffer,
followed by 35 min of no-flow ischemia (37°C) and
60 min reperfusion; (IR-Low-Pre) hearts received low-
dose SC79 for 30 min before ischemia; (IR-Low-Post)
hearts received low-dose SC79 for the initial 30 min of
reperfusion; (IR-Low-Both) hearts received low-dose
SC79 before ischemia and at reperfusion; (IR-High-Pre)
hearts received high-dose SC79 for 30 min before is-
chemia; (IR-High-Post) hearts received high-dose SC79
for the initial 30 min of reperfusion; (IR-High-Both)
hearts received high-dose SC79 before ischemia and at re-
perfusion. Each group consisted of 11 rats (see “Statistical
analysis” for details on power calculation). Experiments
were conducted in a randomized and blinded fashion.
DMSO and SC79 were aliquoted before the start of the
study, when the aliquots received unique five-digit codes
and were kept frozen until the experiment. Each code was
randomly assigned to one rat. The identity of the vials was
controlled by two colleagues not involved in the study,
and was revealed to the investigators after data were col-
lected from all animals. No animal was arbitrarily ex-
cluded from the study.
Figure 1 SC79 activates cardiac AKT. A: Dose–response experiment in normoxic perfused hearts treated with DMSO or SC79. SC79 activates
AKT in a dose-dependent fashion, as demonstrated by phosphorylation at serine 473. B: Total AKT expression is not changed by SC79. C: Phosphorylation
of GSK-3β at serine 9 (AKT-phosphorylated site). D: Total expression of GSK-3β. E: ATP levels are preserved in SC79-perfused hearts. F: LDH activity was
not detected in SC79-treated hearts. Perfusion buffer from hearts submitted to ischemia-reperfusion (IR) were used as positive control for the LDH activity
experiment. “ua/min”, units of absorbance per minute. Data are shown as mean ± standard error (SE). *, p < 0.05 vs. DMSO; &, p < 0.05 vs. all other groups.
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The buffer perfusate was collected immediately before
ischemia and at reperfusion for quantification of cardiac
enzyme release. Creatine kinase (CK) was quantified by
ELISA (Abcam, kit #ab187396) and lactate dehydrogenase
(LDH) activity was measured with a colorimetric assay
(Thermo Scientific, kit #88953) according to manufacturer’sprotocol. The heart was removed from the rig at the end of
reperfusion (60 min), sliced into 2 mm-thick sections and
stained with 2% triphenyltetrazolium chloride (TTC, di-
luted in phosphate buffer). Stained slices were scanned be-
tween glass slides on a black background. Infarct area was
quantified with the ImageJ software and is presented as per-
centage of total area of the left ventricle.
Figure 2 AKT activation in ischemic hearts. A: Illustrative representation of all experimental groups. “IR”, Ischemia-reperfusion. “Pre”, SC79
administered before ischemia. “Post”, SC79 administered at reperfusion. “Both”, SC79 administered before ischemia and at reperfusion. “Low”
indicates 100nM SC79 and “High” indicates 300nM SC79. B: AKT phosphorylation in normoxic-perfused (N) or ischemic hearts (IR) treated with
DMSO or SC79. C: Total AKT expression; D: Correlation between AKT phosphorylation and GSK-3β phosphorylation. E: Correlation between AKT
phosphorylation and Ribosomal-S6 phosphorylation. The Pearson correlation test was used to analyze the correlations shown in panels D and E.
Number of animals analyzed per group is displayed within the bars. Western blot bands displayed in panels D and E are disposed in the same
group order as in panels B and C. Data are shown as mean ± SE. #, p < 0.05 vs. IR-Control; &, p < 0.05 vs. all other groups.
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Left ventricular samples frozen in liquid nitrogen at the
end of reperfusion were used for these analyses. Samples
were homogenized in RIPA buffer containing proteaseand phosphatase inhibitors (Sigma-Aldrich), and centri-
fuged (20 min, 4°C, 16000 g) to remove pelleted debris.
Total protein content was measured and sample loading
buffer was added, followed by heating (10 min). Proteins
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Life Technologies) and transferred to nitrocellulose
membranes. An internal control sample was added to
each gel in order to allow comparison among samples in
different membranes. Membranes were blocked with 5%
bovine serum albumin for 1 h, incubated with primary
antibodies overnight (4°C) and with secondary anti-
bodies (LICOR Biosciences, UK) for one hour. The fol-
lowing primary antibodies were used (numbers indicate
Cell Signaling product code): AKT (#4685), phospho-
AKTser473 (#4060), GSK-3β (#12456), phospho-GSK-3βser9
(#5558), Ribosomal-S6 protein (#2317) and phospho-
Ribosomal-S6ser240/244 (#5364). GAPDH (Glyceraldehyde
3-phosphate dehydrogenase) was adopted as loading con-
trol (Pierce Antibodies, #MA5-15738). The representative
bands shown in the figures were not modified or rear-
ranged, and illustrate one original gel used in the analysis.
Samples remaining from these experiments were frozen in
liquid nitrogen and stored at −80°C.
ATP content and activity of mitochondrial enzymes
For ATP determination, samples were homogenized and
deproteinized with 5% trichloroacetic acid, the pH was
corrected to 7.4 with Tris-acetate buffer and samples
were immediately analyzed with a bioluminescence assay
using recombinant firefly luciferase (Life Technologies,
kit #A2206). Activity of citrate synthase and 3-hydroxyacyl-
CoA dehydrogenase (HADH) were analyzed with colori-
metric assays, as previously described [18].
Cytosolic levels of cytochrome C
Cytosolic and mitochondrial fractions were isolated by
differential centrifugation (Thermo Scientific, kit #89801).
Both fractions were analyzed by western immunobloting
using an antibody against Cytochrome C (Cell Signal-
ing, #11940). VDAC (Voltage-dependent anion chan-
nel, Abcam, #ab14734) was used as mitochondrial
loading control and GAPDH was used as cytosolic
loading control.
Caspase-3 activity
Caspase-3 activity in left ventricle homogenates was
measured using a specific substrate (DEVD, amino acid
sequence Asp-Glu-Val-Asp) conjugated with 7-amino-
4-methylcoumarin probe, which emits fluorescence
(excitation/emission, 342/441 nm) after proteolytic cleav-
age (Life Technologies, #E-13183). A caspase-3 inhibitor
(Ac-DEVD-CHO) was used in a separate well to confirm
that activity corresponded specifically to caspase-3.
Statistical analysis
The entire strategy for statistical analysis was defined be-
fore the start of the study. In order to calculate sample
size, we conducted a pilot experiment (n = 6) andverified mean infarct size (27.1% as measured in TTC-
stained slices) and variation (standard deviation = 7.6%)
in the exact conditions of the study. We then hypothe-
sized a reduction of 30% in infarct in size (from 27.1 to
18.9%), which is a value considered to be clinically sig-
nificant in human clinical trials [19]. Using these data,
the power analysis (SPSS SamplePower, IBM) indicated
that 11 animals per group would be necessary to detect
a significant effect with 80% power and α < 0.05. Normal
distribution of the data was confirmed by the Shapiro-
Wilk test. The Grubbs’ test was used to detect outliers
(α < 0.05). Groups were compared by one-way analysis of
variance (ANOVA) followed by the Fisher post hoc test.
A p-value below 0.05 was considered significant.
Results
Cardiac AKT activation by SC79
Normoxic perfused hearts receiving SC79 for 30 min
displayed a dose–response pattern of AKT activation
(Figure 1A), as assessed by phosphorylation at serine
473. Activation was not significant with 10 or 30nM
doses. 100nM SC79 increased AKT phosphorylation by
1.88 fold above DMSO group (p = 0.028), while max-
imum effect was observed with a dose of 300nM (2.81
fold increase in AKT phosphorylation, p = 0.0001)
(Figure 1A). 900nM SC79 did not increase AKT phos-
phorylation above that observed with 300nM. Total ex-
pression of AKT was not altered by SC79 (Figure 1B). In
order to confirm AKT overactivation, we assessed phos-
phorylation of GSK-3β at serine 9, a direct target of AKT.
Indeed, activation of AKT by SC79 led to phosphorylation
of GSK-3β (Figure 1C), without changes in total GSK-3β
abundance (Figure 1D).
We also asked the question of whether SC79 itself
could be toxic to the heart. To clarify this point we
assessed cardiac ATP levels and LDH release from the
hearts perfused with SC79 (10-900nM) under normoxic
conditions. Importantly, the doses we used of SC79 were
not harmful to perfused hearts, since ATP levels
remained preserved (Figure 1E) and LDH activity was
not detected in the perfusion buffer (Figure 1F), indicat-
ing that no damage was caused by the compound.
The results described above provided the doses to be
used in the protocols with ischemic hearts. The proto-
cols are illustrated in Figure 2A. Phosphorylation of
AKT was increased (Figure 2B) in ischemic hearts when
compared to normoxic perfused heart, while total AKT
abundance was reduced (Figure 2C), as previously dem-
onstrated [20]. The increase in phosphorylation was ob-
served even when phospho-AKT levels were not
corrected for total AKT. Overactivation of AKT by SC79
was maintained until the end of reperfusion, except in
the group receiving a low dose of the compound exclu-
sively before ischemia (Figure 2B, “IR-Low-Pre” group).
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Ribosomal-S6 protein (indirect downstream target of
AKT) correlated significantly with AKT phosphorylation
in our cohort (Figures 2D and E). Total expression of
GSK-3β and Ribosomal-S6 protein were not altered by
ischemia or SC79 (not shown).ATP content and mitochondrial enzyme activity
Disrupted energy metabolism is a hallmark of ischemia
and an important endpoint in studies on cardioprotec-
tion [4,21]. ATP content was largely reduced in hearts
submitted to ischemia (Figure 3A). ATP depletion was
similar among IR-Control and all SC79-treated groups
(Figure 3A). We also assessed maximal activity of mito-
chondrial enzymes HADH (essential for beta-oxidation
of fatty acids) and citrate synthase (pace-making enzyme
for the first step of the Krebs cycle). Surprisingly, activity
of HADH (Figure 3B) and citrate synthase (Figure 3C
and D) were not affected by ischemia, suggesting that
the reduced ATP content was due to dysfunction of
mitochondrial complexes rather than loss of mitochon-
dria. SC79 did not affect activities of HADH (Figure 3B)
or citrate synthase (Figure 3C and D).Figure 3 Cardiac ATP content and mitochondrial enzyme activity. A: C
B: 3-hydroxyacyl-CoA dehydrogenase (HADH) activity. C: Citrate synthase a
mitochondria. Data are shown as mean ± SE. &, p < 0.05 vs. all other groupApoptosis
Release of cytochrome C from mitochondria to cytosol
activates caspase-3, which is a central mechanism in the
execution of cardiomyocyte cell death by apoptosis in
humans [19,22]. Our data show that activation of AKT
by SC79 did not prevent accumulation of cytosolic cyto-
chrome C (Figure 4A) or overactivation of caspase-3
(Figure 4B) caused by ischemia. Original representative
western blots of cytochrome C are shown in Figure 4C.Ischemic damage and infarct size
Cardiac release of intracellular enzymes and infarct size
are important predictors of prognosis and mortality after
MI, and are used as primary outcome in clinical studies
[5,6]. Abundance of CK and LDH was below detection
limit in most of the hearts submitted to normoxic perfu-
sion (Figures 5A and B). SC79 administered before is-
chemia or at reperfusion did not significantly reduce
cardiac release of CK (Figure 5A) and LDH (Figure 5B).
Similarly, SC79 did not promote survival of myocardial
tissue after ischemia, as evidenced by the data on infarct
size (Figure 5C). Figure 5D shows representative cross
sections of the left ventricle after TTC staining.ardiac ATP content at the end of reperfusion. LV, left ventricle.
ctivity in heart homogenates. D: Citrate synthase activity in isolated
s.
Figure 4 Cytosolic cytochrome C and caspase-3 activity. A: Cytochrome C abundance in cytosol. B: Proteolytic activity of caspase-3. RFU/min/
mg, relative fluorescence unit/minute/mg protein. C: Original representative western blots of cytochrome C (Cyt. C). GAPDH and VDAC were used
as cytosolic and mitochondrial loading controls, respectively. A heart homogenate sample was used as gel internal control. Data are shown as
mean ± SE. &, p < 0.05 vs. all other groups.
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This is the first study to determine whether acute
pharmacological activation of AKT protects the myocar-
dium against ischemic damage. Here we show that
SC79, a small molecule activator of AKT, fails to reduce
ischemic injury of the heart. SC79 administered in low
or high doses, before or after ischemia, neither preserved
cardiac ATP content nor prevented overactivation of
caspase-3, a central player in apoptosis. Consequently,
we did not observe significant reduction of infarct size
or cardiac injury biomarkers (CK and LDH). Our data
are surprising and differ from previous studies with gen-
etic models of cardiac AKT overexpression [13-15]. Fun-
damental differences between the models (transgenic vs.
small molecule) certainly account for the distinctive
findings, and our results demonstrate that the protection
observed in transgenic animals is not reproduced by a
potentially therapeutic molecule (SC79). Two crucial is-
sues to be considered are the strategy for AKT activation
and timing. In our study, overactivation of AKT was in-
duced acutely by a small molecule, via a post-translational
mechanism where AKT becomes more susceptible to
phosphorylation without changes in total expression [16]
(Figures 1 and 2). Differently, Matsui et al. studied 9 to
12-week old transgenic mice with cardiac-specific expres-
sion of an active mutant form of AKT (myr-AKT) [15],while in two other studies cardiac overexpression of myr-
AKT was induced by transfection with recombinant
adenovirus at least 48 h before induction of ischemia
[13,14]. The same authors reported that the myr-AKT
transgene caused remarkable changes in cardiac gene ex-
pression profile [23], inducing differential expression of
several genes previously unrelated to AKT signaling and
not involved in canonical signaling downstream of AKT.
This transcriptional response is thought to mediate the
cardioprotective mechanism in these mice because
phosphorylation of canonical AKT targets (e.g. BAD
and GSK-3β) was not affected in the model [23], or in
animals transfected with myr-AKT in adulthood [14].
On the other hand, hyperactivation of AKT by SC79 in the
short timescale of our study (30-60 min) is unlikely to exert
such profound changes on gene transcription, which might
account for the lack of cardioprotection. Additionally,
overexpression of myr-AKT over a 48 h period improves
mitochondrial efficiency and ATP production in isolated
cardiomyocytes under normoxic conditions [24], which
contributed to increased tolerance to hypoxia at a later
time. However, our results show that short-term activation
of AKT with SC79 did not increase ATP levels at reperfu-
sion or improve mitochondrial enzyme activity in ischemic
hearts (Figure 3). Moreover, cardiac-specific overexpres-



























































































































































































Figure 5 Ischemic injury. A: Abundance of creatine kinase in the perfusion buffer at reperfusion. B: Activity of lactate dehydrogenase (LDH) in
the perfusion buffer at reperfusion. C: Infarct size as measured by histology after staining with Triphenyltetrazolium chloride. D: Representative
histological sections of the left ventricle; Each dot within the bars represents one animal of the group. Note that IR-Low-Post shows 10 animals in
panels “A” and “B” because one rat was detected as an outlier for these measurements. Other groups show data from all 11 animals. Data are
shown as mean ± SE. &, p < 0.05 all other groups.
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clearly a chronic adaptation that confers a huge advantage
in the context of ischemia-reperfusion injury. It is also im-
portant to notice that although these studies provided a
valuable and robust proof-of-concept, their clinical impli-
cations are limited. Genetic activation of AKT in these
studies was achieved either during embryonic stages or in-
duced as a preventive measure, days or weeks before the
infarction. Differently, the clinical scenario of acute MI is
totally unpredictable and therefore requires intervention
immediately before ischemia (i.e. at the onset of symp-
toms) or most preferably at reperfusion (i.e. during percu-
taneous coronary intervention or coronary bypass graft
surgery). This requirement is met by cell-permeable small
molecules with rapid action, which justifies the design of
our protocols (Figure 2A).
The rationale presented up to now is compelling to
discern our findings from those obtained with genetic
manipulation of AKT, but it is still insufficient to explain
why treatment with SC79 before ischemia or at reperfu-
sion failed to mimic the effects of ischemic pre- and
postconditioning, respectively. Ischemic conditioning isan acute cardioprotective intervention that induces post-
translational activation of AKT, which is mirrored by
SC79 both in magnitude and timing [26] (Figures 1A
and 2B). In this sense, it was shown that mice lacking
AKT cannot be protected by ischemic preconditioning
[11], what is corroborated by the findings that pharma-
cological blockage of Pi3k-mediated AKT activation im-
pedes the effects of ischemic conditioning [8-10].
Despite these facts, other studies also proved that cardi-
oprotection is abolished when inhibitors of ERK1/2
(Extracellular signal-regulated kinases) [27], JAK (Janus
kinase) [28] or protein kinase C [29] are applied together
with ischemic conditioning. The same results were ob-
served after blockage of adenosine receptors [30], mito-
chondrial potassium channels [31], protein kinase A [32]
or other less studied proteins. These studies form a
strong body of evidence showing that ischemic condi-
tioning induces a highly orchestrated rearrangement of
intracellular signaling, where activation of many individ-
ual players seems to be necessary. Although AKT clearly
is one of those players, it does not seem to be sufficient.
In this regard, it is also important to notice that most
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cardioprotection by blocking the entire cascade down-
stream of Pi3k, using the non-selective inhibitors
Wortmannin or LY294002 [8,9,10,13]. These chemicals
are known to block cellular events independent of
AKT [33], and a study suggested a Pi3k-mediated,
AKT-independent mechanism is also implicated in car-
dioprotection against ischemia [34]. It has also been
suggested that chronic (life-long), excessive activation
of AKT could lead to negative feedback inhibition of
Pi3k and indirectly block protective signaling in the heart
[34]. This is very unlikely to be the case in our study be-
cause the stimulus for AKT activation was acute, and the
magnitude of activation reported here is largely similar to
what is obtained after ischemic preconditioning and re-
mote ischemic preconditioning, as mentioned above.
One could also ask whether unspecific molecular sig-
naling induced by SC79 could have blocked a potential
cardioprotective effect of the drug. The only evidence re-
garding specificity of SC79 is provided by the original
study that described the molecule, and the findings show
that SC79 binds specifically the PH domain of Akt [16].
They also show the effect of SC79 does not require insu-
lin, activation of signaling upstream of Akt (Pi3k) or
membrane receptors (e.g. G-protein coupled receptors).
These facts indicate that action of SC79 is totally inde-
pendent of blood serum factors. Additionally, four other
studies have applied SC79 in vitro or in vivo, and have
not reported evidence that the molecule has off-target
effects [35-38]. However, considering that these studies
were not designed with the clear goal to address specifi-
city of SC79, we cannot completely rule out the possibil-
ity that SC79 interacts with proteins other than AKT
and interferes with cardioprotective signaling indirectly.
Nevertheless, a recent study showed that SC79 alone in-
duced glucose uptake in lymphocytes by promoting
translocation of GLUT1 (Glucose Transporter 1) to the
cell membrane [38]. In the context of cardiac ischemia,
stimulation of glucose uptake without compensatory in-
crease of intracellular glucose oxidation could be detri-
mental and prevent a potential benefit of SC79 [39,40].
On the other hand, cardioprotection is detectable when
higher glucose uptake is matched by increased glucose
oxidation and consequent production of ATP, which is
the scenario observed in ischemic preconditioning [41],
exercise training [42,43] or after chemical activation of
AMPK (AMP-activated protein kinase α) [44], a well-
known stimulator of glucose uptake and oxidation.
In summary, our discovery shows that acute administra-
tion of SC79 does not recapitulate the benefits of chronic
AKT activation shown in previous studies, and also suggest
that the pursuit of pharmacological cardioprotection may
require concomitant activation of multiple intracellular tar-
gets, which is an endeavor for future studies in the field.Finally, it is important to emphasize that our findings
by no means challenge the mechanistic hypotheses of
the studies mentioned in this discussion. The hypothesis
of the present study has never been tested before, par-
ticularly because SC79 is the first specific pharmaco-
logical activator of AKT described in the literature [16].
Using this therapeutically relevant strategy, we sought to
investigate outcomes that are used in the clinic (release
of cardiac injury biomarkers and infarct size). However,
a protective effect of SC79 was not confirmed.
Conclusion
We conclude that acute pharmacological activation of
AKT alone by SC79 is not a sufficient condition to evoke
cardioprotection against ischemia in rats.
Limitations
All rats used in this study were young and without
comorbities, which is a condition that is the relatively
different from that of most infarcted patients. These pa-
tients are usually older and have at least one major co-
morbidity, such as diabetes or hypertension. However,
age and comorbidities are known to interfere with AKT
activation and cardioprotection [26,45], and would there-
fore be confounding factors in our analysis.
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